RECRUITING

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.

Official Title

Evaluation of Milk Polar Lipids on Lipoprotein Metabolism, Inflammation, and Gut Microbiota in Dyslipidemic Adults With Abdominal Obesity

Quick Facts

Study Start:2023-10-20

Study Completion:2025-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05700916

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* LDL-C ≥ 130 mg/dL * Waist circumference ≥ 88 cm for women, ≥ 102 cm for men * Aged 18 to 70 years	* Renal disease * Liver disease * Diabetes * Heart disease * Stroke * Cancer * Eating disorders * Thyroid disease * Gut-associated pathologies * Autoimmune diseases * Chronic inflammatory diseases * Scleroderma * Gallbladder disease * Blood clotting disorders * Intravenous drug use * Fasting plasma/serum triglycerides \>500 mg/dL * Fasting plasma/serum glucose \>126 mg/d * Weight changes \>10% over last 4 weeks * Oral antibiotics use up to 1 month prior to and during study * Allergy or intolerance to milk products * Taking lipid-lowering medications (e.g., statins, fibrates) * Taking anti-inflammatory medications (e.g., corticosteroids) * Taking medications which primarily affect blood clotting (e.g., warfarin).

Inclusion Criteria

Exclusion Criteria

* LDL-C ≥ 130 mg/dL
* Waist circumference ≥ 88 cm for women, ≥ 102 cm for men
* Aged 18 to 70 years

* Renal disease
* Liver disease
* Diabetes
* Heart disease
* Stroke
* Cancer
* Eating disorders
* Thyroid disease
* Gut-associated pathologies
* Autoimmune diseases
* Chronic inflammatory diseases
* Scleroderma
* Gallbladder disease
* Blood clotting disorders
* Intravenous drug use
* Fasting plasma/serum triglycerides \>500 mg/dL
* Fasting plasma/serum glucose \>126 mg/d
* Weight changes \>10% over last 4 weeks
* Oral antibiotics use up to 1 month prior to and during study
* Allergy or intolerance to milk products
* Taking lipid-lowering medications (e.g., statins, fibrates)
* Taking anti-inflammatory medications (e.g., corticosteroids)
* Taking medications which primarily affect blood clotting (e.g., warfarin).

Contacts and Locations

Study Contact

Christopher N Blesso, Ph.D.

CONTACT

860-486-9049

christopher.blesso@uconn.edu

Study Locations (Sites)

University of Connecticut

Storrs, Connecticut, 06269

United States

Collaborators and Investigators

Sponsor: University of Connecticut

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-20

Study Completion Date2025-12

Study Record Updates

Study Start Date2023-10-20

Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

Dyslipidemias
Obesity